Skip to main navigation menu Skip to main content Skip to site footer
×
English | Spanish
Editorial
Current Archives
Original

Application and mechanism of Action of lisdexamfetamine (ldx) in The treatment of attention and compulsion disorders

By
Camila Andrada Santos ,
Camila Andrada Santos

Facultad de Medicina y Ciencias de la Salud Universidad Abierta Interamericana

Search this author on:

PubMed | Google Scholar
Marcelo Adrian Estrin ,
Marcelo Adrian Estrin

Facultad de Medicina y Ciencias de la Salud Universidad Abierta Interamericana

Search this author on:

PubMed | Google Scholar

Abstract

Background: Attention Deficit Hyperactivity Disorder (ADHD), widely known as attention deficit disorder, currently represents a critical issue in the fields of public health and mental health, affecting populations from childhood to adulthood. It is estimated that 3% of the adult population is affected by this disorder, and this has significant implications in the daily lives of affected individuals. 
Patients experiencing ADHD often face notable difficulties in areas such as maintaining attention, impulse regulation, and behavioral control. Characteristic symptoms include inattention, hyperactivity, and impulsivity. ADHD is addressed therapeutically through a multidisciplinary approach that combines behavioral therapies and the use of medicinal agents, including both stimulant and non-stimulant drugs. These therapeutic resources help improve the ability to concentrate, impulse control, and, therefore, the quality of life of affected individuals. In recent years, Lisdexamfetamine has gained prominence as a first-line therapeutic alternative in the treatment of ADHD, standing out for its superior efficacy compared to predecessor agents such as methylphenidate (marketed under the name Ritalin), modafinil, guanfacine, and paroxetine. In addition to its application in the context of ADHD, lisdexamfetamine is being explored as an adjuvant intervention in the treatment of binge eating disorder. This disorder is characterized by recurrent episodes of excessive food intake in a short period, accompanied by a perception of a lack of control during such episodes. Binge eating can lead to physical and emotional distress and have a negative impact on the overall health and well-being of affected individuals. Lisdexamfetamine is proposed as a possible solution to alleviate the symptoms of binge eating disorder, with the potential to reduce the frequency of compulsive episodes and promote a greater perception of control over eating. Material and methods: A systematic review will be carried out that includes exploration in databases such as Pubmed and Google Scholar, using filters related to Attention Deficit Disorder, Binge Eating Disorder, and adverse effects. Results: 8 randomized trial articles were used, searched in the databases, and filtered based on the last two years, where the application and mechanism of LISDEXAMPHETAMINE (LDX) in the treatment of attention and compulsive eating disorders were evidenced. Conclusion: After the search carried out, it is understood that LISDEXAMPHETAMINE (LDX) in recent years has gained prominence as a first-line therapeutic alternative in the treatment of ADHD, standing out for its superior efficacy compared to predecessor agents. However, other specialized studies are also required to evaluate possible side effects, both therapeutic and adverse effects

How to Cite

1.
Andrada Santos C, Estrin MA. Application and mechanism of Action of lisdexamfetamine (ldx) in The treatment of attention and compulsion disorders . SCT Proceedings in Interdisciplinary Insights and Innovations [Internet]. 2024 Jun. 11 [cited 2024 Jul. 18];2:322. Available from: https://proceedings.saludcyt.ar/index.php/piii/article/view/322

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.